Skip to main content
. 2016 Jun 19;22(10):807–816. doi: 10.1111/cns.12572

Figure 1.

Figure 1

Efficacy of tolerogenic vaccination with MOG+VitD in EAE exacerbated by C. albicans infection. Experimental design (A); vaccination procedure included eight VitD doses administered every other day and two MOG doses injected at days ‐16 and ‐8. One day after last VitD dose, C57BL/6 mice were infected with C. albicans, and 3 days after, they were submitted to EAE induction. Peripheral and local immunological parameters were assessed in early clinical and clinical disease phases, 10th and 17th days after EAE induction, respectively. Clinical score (B) and body weight (C) were daily recorded until the 17th day. The percentage of weight variation was determined during vaccination, that is from day ‐19 to day 0 (D) and during EAE development, that is, from day 0 to day 17 (E). The results are expressed as mean ± SD (6–7 mice/group), one experiment representative of two is shown. (B,C) # indicates difference between vaccinated and nonvaccinated groups; * indicate difference between EAE and Ca/EAE groups. (D,E) **P < 0.01 and ***P < 0.001 indicate difference between vaccinated and nonvaccinated groups.